Tscan Therapeutics Inc

NASDAQ:TCRX   4:00:00 PM EDT
2.31
-0.04 (-1.70%)
Earnings Announcements

Tscan Therapeutics Reports Third Quarter 2022 Financial Results And Provides Business Update

Published: 11/09/2022 12:30 GMT
Tscan Therapeutics Inc (TCRX) - Tscan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update.
Ended Quarter With Cash and Cash Equivalents of $137.3 Million, Funding Operations Into 2q'24.
Qtrly Loss per Share $0.67.
Q3 Earnings per Share View $-0.72 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $4.1 Million
Adjusted EPS is expected to be -$0.72

Next Quarter Revenue Guidance is expected to be $4.61 Million
Next Quarter EPS Guidance is expected to be -$0.70

More details on our Analysts Page.